Clinical Outcome of Acute Lymphocytic Leukemia with Concurrent MLL Gene Rearrangement and t (9; 22) in the Era of Tyrosine Kinase Inhibitors

The outcome of ALL with t(9;22) (Ph+ve) have considerably improved with tyrosine kinase inhibitors (TKI) based induction chemotherapy. We sought to evaluate the outcome of ALL patients with concurrent MLL gene rearrangement (MLL) and Ph +ve in the era of TKI.

Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Talha Badar, Hagop Kantarjian, Jorge Cortes, Elias Jabbour, Guillermo Garcia-Manero, Susan O'Brien, Farhad Ravandi Source Type: research